Clinical Trial Update: Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluating the steroid-sparing effect of omalizumab (Xolair) in patients with eosinophilic bronchitis and steroid-dependent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Bronchitis

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: McMaster University | Conditions: Steroid and/or Prednisone Dependent Asthma, Eosinophilic Bronchitis | Phase 2, Phase 3 | Status: COMPLETED